Royalty Pharma (RPRX) Interest & Investment Income (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Interest & Investment Income data on file, last reported at $6.2 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 44.83% year-over-year to $6.2 million; the trailing twelve-month figure through Mar 2026 stood at $28.5 million (down 44.29% YoY), and the FY2025 full-year result was $33.6 million, down 29.05% from the prior year.
• Interest & Investment Income fell to $6.2 million in Q1 2026, from $7.1 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $43.9 million in Q4 2022 to a low of $6.2 million in Q1 2026.
• A 5-year average of $14.0 million and a median of $10.9 million in 2022 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income surged 312.19% in 2022 and sank 85.18% in 2023, its largest moves.
• Tracing RPRX's Interest & Investment Income over 5 years: stood at $43.9 million in 2022, then slumped by 85.18% to $6.5 million in 2023, then jumped by 39.03% to $9.0 million in 2024, then retreated by 21.76% to $7.1 million in 2025, then decreased by 11.91% to $6.2 million in 2026.
• Business Quant data shows RPRX's Interest & Investment Income at $6.2 million in Q1 2026, $7.1 million in Q4 2025, and $6.9 million in Q3 2025.